2026-04-18T02:23:12Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2195232025-12-05T11:08:13Zcom_2072_1057col_2072_478780col_2072_478917

00925njm 22002777a 4500 dc Caporali, Sabrina author Butera, Alessio author Ruzza, Alessia author Zampieri, Carlotta author Bantulà, Marina author Scharsich, Sandra author Ückert, Anna-Katerina author Celardo, Ivana author Kouzel, Ian U. author Leanza, Luigi author Gruber, Andreas author Montero Boronat, Joan author D'Alessandro, Angelo author Brunner, Thomas author Leist, Marcel author Amelio, Ivano author 2025-03-06T19:00:34Z 2025-03-06T19:00:34Z 2024-11-26 2025-03-06T19:00:34Z Background: Approximately half of all human cancers harbour mutations in the p53 gene, leading to the generation of neomorphic p53 mutant proteins. These mutants can exert gain-of-function (GOF) effects, potentially promoting tumour progression. However, the clinical significance of p53 GOF mutations, as well as the selectivity of individual variants, remains controversial and unclear. Methods: To elucidate the metabolic regulations and molecular underpinnings associated with the specific p53R270H and p53R172H mutant variants (the mouse equivalents of human p53R273H and p53R175H, respectively), we employed a comprehensive approach. This included integrating global metabolomic analysis with epigenomic and transcriptomic profiling in mouse pancreatic cancer cells. Additionally, we assessed metabolic parameters such as oxygen consumption rate and conducted analyses of proliferation and cell-cell competition to validate the biological impact of metabolic changes on pancreatic ductal adenocarcinoma (PDAC) phenotype. Our findings were further corroborated through analysis of clinical datasets from human cancer cohorts. Results: Our investigation revealed that the p53R270H variant, but not p53R172H, sustains mitochondrial function and energy production while also influencing cellular antioxidant capacity. Conversely, p53R172H, while not affecting mitochondrial metabolism, attenuates the activation of pro-tumorigenic metabolic pathways such as the urea cycle. Thus, the two variants selectively control different metabolic pathways in pancreatic cancer cells. Mechanistically, p53R270H induces alterations in the expression of genes associated with oxidative stress and reduction in mitochondrial respiration. In contrast, p53R172H specifically impacts the expression levels of enzymes involved in the urea metabolism. However, our analysis of cell proliferation and cell competition suggested that the expression of either p53R270H or p53R172H does not influence confer any selective advantage to this cellular model in vitro. Furthermore, assessment of mitochondrial priming indicated that the p53R270H-driven mitochondrial effect does not alter cytochrome c release or the apoptotic propensity of pancreatic cancer cells. Conclusions: Our study elucidates the mutant-specific impact of p53R270H and p53R172H on metabolism of PDAC cancer cells, highlighting the need to shift from viewing p53 mutant variants as a homogeneous group of entities to a systematic assessment of each specific p53 mutant protein. Moreover, our finding underscores the importance of further exploring the significance of p53 mutant proteins using models that more accurately reflect tumor ecology. Càncer de pàncrees Metabolisme Antioxidants Proteïnes supressores de tumors Pancreas cancer Metabolism Antioxidants Tumor suppressor protein Selective metabolic regulations by p53 mutant variants in pancreatic cancer